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84. INTRODUCTION
4.1 EPILEPSY
Epilepsy is one of the most common brain disorders. The term “epilepsy” has been used 
since 500 BC and translates literally to ‘attack’ or ‘assault’. Throughout history, persons 
suffering from epilepsy have been regarded as being possessed by evil spirits, and the disease 
has also been termed “the sacred disease”. Theories on the causes of epilepsy have varied 
from invasion by demons, to shifting lunar phases, to sexual obsession or masturbation. Thus 
associations between cyclicity and seizures, and between gender and epilepsy, have been 
suspected since ancient times, but on a very different basis from our understanding today.
In developed countries, the prevalence of active epilepsy is 0.7 % (Hauser et al., 1996;
Keränen and Riekkinen, 1989), while the incidence is about 50 per 100,000 persons (Hauser 
et al., 1996; Olafsen et al., 2005). Extrapolated to Norwegian conditions, this is approximately
2,000 patients receiving an initial diagnosis of epilepsy in Norway annually and a total of 
30,000 of the Norwegian population suffering from epilepsy. The disease probably has an 
approximately equal distribution amongst men and women in Norway, as found in Iceland
(Olafsen et al., 2005) and Sweden (Brorson, 1970), or there might be a slight predominance of 
males (Forsgren, 1992; Keränen et al., 1989).
Epilepsy is a chronic condition, characterized by recurrent, unprovoked epileptic seizures 
(ILAE (International League Against Epilepsy) commission report, Fisher et al., 2005). An 
epileptic seizure is a transient occurrence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity in the brain (Fisher et al., 2005). Epilepsy usually 
has neurobiological, cognitive, psychological, and social consequences (Fisher et al., 2005).
Epilepsy affects people in all age groups, with the highest incidence in the first year of 
life, and in the elderly above 65 years (Hauser et al., 1993; Olafsson et al., 2005). Thus the
disease affects numerous men and women of fertile age and several aspects of the condition, 
particularly regarding fertility, pregnancy, and sexual life, are of great importance to the 
patients.
Epileptic seizures can differ widely in presentation, and in order to optimise effective 
treatment, systematic classification systems are necessary. The currently valid ILAE 
‘Classification of Epileptic Seizures’ was devised in 1981 and is based on clinical and EEG 
manifestations. Seizures are principally divided into partial and generalized seizures, but some 
seizures are unclassified. In adults, partial seizures are most common, accounting for 60 – 70
% of all seizures (Hauser et al., 1993; Forsgren et al., 1996; Oun et al., 2003).
94.2 HORMONES
Hormones are chemical messengers carried by blood or lymph vessels to act on cells or 
organs distant from their original sites of secretion. When hormones are secreted into the 
bloodstream, many immediately bind to plasma proteins with high specificity and affinity. 
Sex hormones (oestrogens, testosterone, and DHT) bind to a protein called SHBG (sex 
hormone binding globulin) and also to albumin, but with a much lower affinity. Prolactin is 
transported in plasma by the protein transcortin or corticosteroid binding protein (CBG). 
Equilibrium is established between free and bound hormone; the greatest proportion of 
hormones are carried and bound, and only the free, unbound portion is physiologically active. 
Protein binding of hormones is of importance for drug interactions, because some drugs 
displace hormones from their binding site.
Hormones can also either bind directly, or through secondary messengers, to DNA 
(chromatin) thereby affecting gene transcription and the production of the respective mRNAs. 
This alters the quantities of specific proteins and therefore impacts on metabolic processes.
4.2.1 The hypothalamus and the pituitary gland 
The pituitary gland consists of two major components: the adenohypophysis and the 
neurohypophysis. The adenohypophysis consists of the anterior lobe and the rudimentary 
intermediate lobe. The anterior pituitary secrets a number of hormones that regulate the 
growth and function of other endocrine glands or influence metabolic functions in target 
tissues. These include growth hormone (GH), thyroid-stimulating hormone (TSH), prolactin,
luteinizing hormone (LH), follicle-stimulating hormone (FSH), and adrenocorticotropic 
hormone (ACTH). The release of hormones from the anterior pituitary gland is controlled by 
releasing hormones from the hypothalamus. Gonadotropin-releasing hormone (GnRH) is 
produced in the hypothalamus and controls the secretion of LH and FSH from the pituitary 
gland. Hypothalamic hormones are released from the hypothalamic nerve fibre endings 
around the capillaries of the hypothalamic-hypophyseal system in the pituitary stalk, and 
reach the anterior lobe through a special portal system that connects the hypothalamus and the 
anterior lobe (Figures 1 and 2).
The neurohypophysis consists of the infundibular process, or posterior lobe. The posterior 
pituitary contains two active hormones, antidiuretic hormone (ADH) and oxytocin. Both 
hormones are produced in the hypothalamus and transported by axoplasmatic flow to nerve 
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endings in the posterior pituitary, where they are released into circulation via appropriate 
stimulation.
Regions of the hypothalamus that are involved in the regulation, production, and 
secretion of GnRH receive extensive direct connections from the cerebral hemispheres, 
especially from the temporolimbic structures that are commonly involved in epilepsy, and 
most notably from the amygdala.
The gonadotropins (FSH, LH, and hCG): These hormones are responsible for 
gametogenesies and steroidogenesis in the gonads. Human chorionic gonadotropin (hCG) is a 
pregnancy hormone which is synthesized in the placenta.
FSH binds to specific receptors on the plasma membrane of the follicular cells in the 
ovaries and the Sertoli cells in the testes. Adenylate cyclase acts as the intracellular 
messenger. FSH promotes follicular growth and prepares the follicles for the ovulation-
inducing action of LH, and enhances the LH-induced release of oestrogens. In the male, FSH
binds to the Sertoli cells, where it induces the synthesis of an androgen-binding protein 
involved in the transport of testosterone to the seminiferous tubuli and epididymis. This is 
important for achieving the high local levels of testosterone required for spermatogenesis.
FSH stimulates seminiferous tube and testicular growth and is important in initiating 
spermatogenesis.
LH binds to specific plasma membrane receptors and stimulates the production of 
progesterone by the corpus luteum and testosterone by the Leydig cells. Cyclic adenosine 
monophosphate (cAMP) acts as an intracellular messenger for LH. The LH spike in the 
middle of the menstrual cycle triggers ovulation. LH can stimulate interstitial cells in the 
ovaries to produce a number of androgens and androgen precursors (androstenedione, 
dehydroepiandrosterone, and testosterone). Women with polycystic ovary syndrome (PCOS) 
have elevated LH concentrations and increased androgen production. In males, LH stimulates 
testosterone production.
Regulation of FSH and LH: Secretion of LH and FSH is regulated by a classic feedback
loop, regulated by the gonadal steroid hormones. Sex hormones administered for a prolonged 
period will inhibit the secretion of LH and FSH. Positive feedback control is also involved, 
since oestradiol is responsible for the ovulatory burst of LH. The secretion of LH and FSH is 
regulated by a single hypothalamic releasing factor, GnRH. GnRH release is inhibited by the 
target organ hormones, testosterone and oestradiol, and by endorphins. GnRH release is 
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stimulated by dopamine, alpha adrenergic agents, and prostaglandins. Although separate 
releasing factors have not been found, plasma FSH and LH do not always change 
concordantly. In the testicles another factor, inhibin, inhibits FSH release.
Prolactin: Prolactin is involved in initiation and maintenance of lactation. Excessive prolactin 
secretion can cause amenorrhoea and galactorrhoea. In men, excessive prolactin is associated
with gynecomastia and impotence.
4.2.2 The gonadal hormones
OVARY: Oestrogens: oestrogens are a family of hormones synthesized in the ovaries or in 
extra ovarian tissues. 17ß-oestradiol is the primary oestrogen of ovarian origin. In pregnancy
relatively more oestriol is produced (extra ovarian). In and after menopause, oestrone is the 
main oestrogen in women. Oestradiol is mainly produced in granulosa cells in the ovaries.
Oestrogens are formed by aromatization of androgens. Increased activity of these enzymes 
results in “oestrogenization”. Oestrogens stimulate the development of tissues involved in 
reproduction. Under oestrogen stimulation, the vaginal epithelium and uterine endometrium 
proliferates, the myometrium matures, and breast ducts proliferate. Oestrogens also have an 
anabolic effect on bone and cartilage, promote growth, and are responsible for most secondary 
sexual characteristics in the female.
Progesterone: Progesterone is synthesized and secreted by the corpora lutea. As with
oestrogens and testosterone, progesterone is derived from cholesterol (figure 3), but the 
enzyme aromatase is not in the synthesis pathway. Progesterone is metabolized in the liver. 
Progesterone requires a previous or concurrent action of oestradiol to have an effect.
Progesterone reduces the proliferation and growth of vaginal epithelium and converts the 
uterine epithelium from proliferative to secretory. Progesterone enhances development of the 
acinar portion of breastglands after ductal development has been stimulated by oestrogens.
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Figure 1. Female sexual hormones
TESTES: Androgens: Testosterone is synthesized in the Leydig cells in the testicles, under 
the influence of LH. Testosterone is the major hormone produced in the foetus, but testes only 
produce androsterone after birth. The ability to produce testosterone is restored at puberty and 
continues throughout life. The androgens (principally testosterone and 5-alpha-DHT) are 
involved in sexual differentiation, spermatogenesis, development of secondary sexual 
characteristics, anabolic metabolism, and in masculine behaviour patterns. Testosterone is 
important for sexual fantasizing and desire, but is not involved in achieving an erection.
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Figure 2. Male sexual hormones
Figure 3. Biosynthesis of oestrogens
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Puberty: In females, puberty is initiated by a gradual increase in gonadotropic hormones 
from the pituitary gland, beginning in about the eighth year of life. This stimulates a gradual 
increase in oestrogen production, culminating in the first menstruation (menarche) usually 
between 11 and 16 years of age. In males, testosterone is produced in the testes from early
embryonic life and is responsible for the development of male sexual organs. The serum 
concentration of testosterone is low at birth, but increases during the first year of life. From 
the second year of life until onset of puberty, testosterone concentrations are very low, but
from onset of puberty at ages12-13 years, until about age 20 years, plasma testosterone 
increases. Testosterone concentration then remains stable until old age, when it declines.
Menstrual cycle: After menarche, menstruation follows a cyclical, approximately monthly,
pattern. GnRH from the hypothalamus is secreted in 5 to 25 minute pulses, at 1 to 2 hours
intervals.  This causes the anterior pituitary to secrete LH and FSH. The menstrual cycle is 
conventionally described as being 28 days, but may range from 21 to 35 days. On day one, the 
menstrual bleeding starts, and continues for approximately 5 days. At the same time the 
follicular phase starts and the endometrium is built up, preparing to receive a fertilized ovum. 
Under the influence of predominantly FSH, a follicle matures. Ovarian blood flow increases 
and the maturing follicle produces increasing amounts of oestradiol. On day 13, oestradiol 
concentrations peak and, by a positive feedback effect, the surge of GnRH and LH is released. 
This results in a peak in LH, which is necessary for ovulation to occur. At this time, body 
temperature increases by approximately 0.5	
s 14 to 28 is called the luteal phase and is 
characterized by formation of the corpus luteum. The corpus luteum produces mainly 
progesterone, but also some oestradiol. If pregnancy does not occur, the corpus luteum 
gradually involutes. At days 27 and 28 there is a sudden decline in oestradiol and 
progesterone secretion, followed by constriction of the spiral arterioles and development of 
endometrial ischaemia and desquamation; i.e menstruation. (Figure 4).
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Figure 4. Changes during the menstrual cycle
From “The Merck Manuals online medical library”
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4.3 CLINICAL OBSERVATIONS IN MEN AND WOMEN WITH EPILEPSY
4.3.1. Puberty
Onset of puberty can have an effect on epilepsy. Some childhood epilepsies, such as benign 
childhood focal seizures, tend to remit, but puberty may trigger the onset of some other 
epilepsies. Juvenile myoclonic epilepsy typically has its debut around puberty. Several factors 
which are known to influence seizure threshold may alter during the pubertal years. Alcohol 
may be introduced and sleeping habits often change. Life, in general, is often more irregular 
than it was in childhood and reverts to later in adult life. Our knowledge about hormonal 
influences on brain excitability has resulted in the development of a hypothesis that puberty or 
menarche may be important triggers for epilepsy, and associations between onset of epilepsy 
and menarche have been reported for up to 20 - 30 % of female patients (Klein et al., 2003;
Morrell et al., 1998).
4.3.2 Menstrual disturbances
Menstrual disturbances are common among healthy women. A study performed many years 
ago reported menstrual disturbances in up to 27 % of women without epilepsy (Aray, 1939).
In another study of women of reproductive age, 18 % had irregular cycles (Polson et al.,
1988). When comparing studies on menstrual disturbances it is important to consider how 
menstrual disturbances are defined in the individual studies. A common definition used in 
many studies, and defined by Polson in 1988, is a menstrual cycle of less than 22 days or of 
more than 35 days, or duration of bleeding of more than 8 days, or a variation of more than 4 
days in two consecutive periods. Women with epilepsy have been shown to have more 
menstrual disturbances than women without epilepsy (Herzog et al., 1986; Bilo et al., 1988,
2001; Murialdo et al., 1997; Hamed et al., 2007) and also often have amenorrhoea or 
oligomenorrhoea (Herzog et al., 2003; Hamed et al., 2007). Menstrual disturbances are often 
seen in women with polycystic ovaries (PCO), which occur frequently in women with 
epilepsy (Herzog et al., 1984, 1986), and are also associated with the use of valproate
(VPA). PCOS occurs in between 4 and 6 % of women in the general population 
(Knochenhauser et al., 1998; Clayton et al., 1992) and in between 10 and 25 % of women 
with epilepsy, even if they are not receiving antiepileptic drugs (AEDs) (Herzog et al., 1984,
1986; Hamed et al., 2007). The reasons for these disturbances have been debated in depth by 
doctors and other professionals in this field. Are they caused by the epilepsy itself? The 
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medication? Or is the underlying disease or psychosocial factors responsible? Probably all 
these factors play a role, with their contributions varying depending on the individual cases.
The hormonal fluctuations during the menstrual cycle have been regarded as 
relevant for the cyclical pattern of seizures in women with epileptsy. Herzog et al. (1997) 
described three different patterns of epilepsy, associated with different phases in the menstrual 
cycle: 
1) Perimenstrual (Days -3 to 3, when start of menstruation is day 0);
2) Ovulatory (Days 10 to -13);
3) Anovulatory cycles: an increased frequency of seizures in the perimenstrual, luteal (days -
12 to -4), and ovulatory phases, rather than in the follicular phase (days 4 to 9).
This description of catamenial epilepsy has been widely accepted.
4.3.3 Fertility 
People with epilepsy frequently have lower birth rates than the general population. In the 
Rochester study from 1986, fertility in males was reduced to 80 % and to 85 % in women 
(Webber et al., 1986). Several later studies have confirmed this finding (Schupf and Ottman,
1996; Dansky et al., 1980; Artama et al., 2004, 2006). However, in a population-based study 
from Iceland, no difference in birth rate was detected between female epilepsy patients and 
the reference group (Olafson et al., 1998). Alterations in sperm motility and sperm count have 
been found in males with epilepsy; Taneja et al. (1994) showed that both phenytoin (PHT)-
treated and untreated males with epilepsy had reduced sperm motility, and lower seminal fluid 
volumes and spermatozoa concentrations than controls. VPA-treatment has also found to be 
associated with fertility problems and abnormal sperm (Curtis et al. 1994; Yerby and Mc Coy,
1999). Røste et al. (2003) found alterations in semen quality in males treated with either VPA 
or carbamazepine (CBZ) compared with controls.
Fertility rate is a complex issue that is affected not only by the epilepsy itself and the 
associated medication, but is also influenced by the patient’s social and psychological 
situation. The frequency of marriage is lower among epilepsy patients than in the general 
population, but birth rate is also reduced among married patients (Schrumpf et al., 1996;
Dansky et al., 1980). Because epilepsy is a symptom of an underlying brain disease in many 
patients, it can be the underlying disease (inherited diseases, cancer, cerebro-vascular diseases
etc) that causes the reduced fertility, rather than the associated epilepsy. The burden of 
suffering from epileptic seizures and the increased risk of malformations in offspring due to 
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AEDs can influence decisions on having babies. Real infertility only exists if pregnancy does 
not occur despite persistent attempts; this aspect has been studied very infrequently in 
humans.   
4.3.4 Sexuality
According to the diagnostic classification system ICD-10, the definition of sexual dysfunction 
includes “the various ways in which an individual is unable to participate in a sexual 
relationship as he or she would wish”. In a study by Morrell and Guldner (1996), patients with 
localization-related epilepsy (LRE) and primary generalized epilepsy (PGE) reported reduced
sexual arousability. Furthermore, women with LRE reported greater sexual anxiety, more 
dyspareunia and vaginismus, and sexual dissatisfaction, and women with PGE experienced 
dysorgasmia and sexual dissatisfaction.  Bergen et al. (1992) showed that sexual desire was 
significantly lower in a group of female epilepsy patients, without any correlation with type of 
AED used, duration of epilepsy, or seizure type. Diminished sexual interest and activity is 
found in both men and women with temporal lobe epilepsy, and in men this also occurs in 
conjunction with a reduced potency. Comparison of patients with right temporal lobe epilepsy
(RTLE) and left temporal lobe epilepsy (LTLE) by Herzog et al. (2003b), demonstrated that 
women with RTLE had poorer scores in the Arizona Sexual Experience Scale (ASEX) 
questionnaire for measuring sexual function.
Three different mechanisms have been put forward as explanations for these findings. These 
are:
1) Ictal of interictal activity of epileptic foci located in medial temporal limbic structures may 
disrupt hypothalamic regulation of pituitary gonadotropins or prolactin function (Herzog et 
al., 1982, 1986a, b; Pritchard et al., 1983; Spark et al., 1984).
2) Various effects of AEDs on sexual functions (Barragry et al., 1978; Mattson et al., 1985;
Herzog, 1991; Morrell et al., 2005).
3) The psychosocial factors associated with epilepsy (Levin et al., 1988). 
In studies of healthy volunteers, sexual dysfunction has been correlated with depression, 
negative experiences in sexual relationships, and reduction in overall well-being (Laumann et 
al., 1999). Women with epilepsy are often overrepresented in these groups, and it is well 
known that depression is a common problem among epilepsy patients (Morrell et al., 2005).
However, sexual problems are common in most chronic diseases (Schover and Jensen, 1988;
Spector and Carey, 1990) and also occur frequently in healthy persons. 
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Cultural aspects may also be of importance and should be considered when evaluating the 
results of such studies. In a study of out-patients from Egypt (Demerdash et al., 1991), it was 
observed that sexual dysfunction was less common in women with epilepsy than in healthy 
controls in USA, where most such studies are performed.
4.4 INFLUENCES OF EPILEPSY ON HORMONES 
Epilepsy itself can affect reproductive endocrine function. Both animal and human 
studies have demonstrated that hormone levels and reproductive function are altered after 
temperolimbic seizures (Edwards et al., 1999a, b; Feeny et al., 1998). In female rodents,
amygdala seizures can cause anovulation, elevated serum oestradiol, and accumulation of 
ovarian follicular cysts (Edwards et al., 1999a). In male rats, amygdala kindled seizures and 
generalized seizures have been shown to elevate serum testosterone, oestradiol, and prolactin,
and also to disrupt normal gonadal structure (Edwards et al., 1999b). In male cats, amygdala 
kindling has been shown to result in hypo-sexuality and fewer offspring (Feeny et al., 1998).
Unilateral amygdaloidal seizures in rats have been shown to activate specific hypothalamic 
nuclei involved in reproductive endocrine regulation (Silveira et al., 2000), with greatest 
effect ipsilateral to the electric stimulation. This study supports the hypothesis that seizures 
originating from left or right amygdala can result in different reproductive endocrine 
disorders. There is also clinical evidence that epileptiform discharges disrupt the 
temporolimbic modulation of hypothalamo-pituitary function (Sperling et al., 1986; Herzog,
1993). 
LTLE in women is associated with significantly higher pulse frequencies of GnRH secretion 
(Herzog et al., 2003a), which, in turn, are associated with higher LH/FSH ratios and higher 
testosterone levels (Herzog et al., 2003a). This endocrine change is characteristic of PCOS,
and has been associated with the increase in PCOS seen in epilepsy patients. In male rats,
testicular steroidogenesis was suppressed, and serum testosterone concentrations significantly 
decreased, following brain cuts above the amygdala on the left side (Banczerowski et al.,
2003a).
RTLE is associated with lower GnRH pulse frequencies (Herzog et al., 1986, 2003a), which,
in turn, are associated with decreased LH and oestradiol levels. These reductions are
characteristic of hypothalamic amenorrhoea (Herzog et al., 1986, 2003a; Kalinin and 
Zheleznova, 2007). Prolactin elevation commonly follows right lateral discharges (Sperling et 
al., 1986) and generalized seizures (Abbott et al., 1980; Rao et al., 1989). In male rats, a brain 
20
cut above the amygdala on the right side induced a rise in basal testosterone secretion from 
both testes (Banczerowski et al., 2003a), while kainic acid injection in the amygdala resulted 
in a decrease in testosterone (Banczerowski et al., 2003b).
4.5 INFLUENCES OF HORMONES ON EPILEPSY
The sex hormones have been demonstrated to have differing effects on seizure 
susceptibility. The effects of the different sex hormones are described individually in the 
following sections.
4.5.1 Oestradiol
Studies from the 1960s by Logothetis and Harner (1960) and Woolley and Temiras (1962)
showed that oestradiol administration to ovary-ectomized rats resulted in proconvulsant 
effects. Early studies have also shown that application of oestrogens directly to the cerebral 
cortex caused rapid and potent epileptogenic effects (Logothetis et al., 1959; Logothetis and 
Harner, 1960; Marcus and Watson, 1966; Hardy, 1970). Oestradiol has been shown to 
promote kindling in animals (Hom and Buterbaugh, 1986; Buterbaugh, 1989; Edwards et al.,
1999c). Oestradiol also potentiates seizures induced by pentyletetrazol (PTZ) (Nicoletti et al.,
1985; Woolley, 2000). The excitatory effects of oestrogens can be partially explained by their
ability to enhance glutamate-receptor excitatory neurotransmission (Smith et al., 1987, 1988;
Wong and Moss, 1994) and decrease gamma-aminobutyric acid (GABA)-ergic inhibition 
(Murphy et al., 1998). Oestradiol acts on neurons in the limbic system, cerebral cortex, and 
other regions important for seizure susceptibility. This pro-convulsive effect of oestrogens has 
been proposed to be of importance in the variation in seizure susceptibility in different phases 
of a woman’s life.
4.5.2 Progesterone
The first report on progesterone’s anticonvulsant effect in the PTZ test was published by Hans 
Selye (1942). More reports have gradually been published on the anti-seizure effects of 
progesterone, from both animal and human studies (Craig and Deason, 1968; Landgren et al.,
1978; Herzog, 1995, 1999a, b; Lonsdale and Burnham, 2007; Taubøll et al., 1993a, c, 1994;
Taubøll and Gjerstad, 1993b). Progesterone and its metabolites directly influence brain 
excitability through a steroid site on or near the GABA/benzodiazepine receptor-chloride 
ionophore complex (Majewska et al., 1986; Harrison et al., 1987; Gee et al., 1987, 1988;
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Peters et al., 1988; Turner et al., 1989). The effect of progesterone and its metabolites is 
similar to that of barbiturates, but they do not share a common site of action on the GABAA
receptor complex. The steroids have been shown to prolong the effective open time of the 
chloride channels, thereby inhibiting excitation of neurons (Barker et al., 1986). This contrasts 
with the findings for benzodiazepines and barbiturates, which mainly act by increasing the 
frequency of GABA-channel openings (Study and Barker, 1981). In addition to the GABA 
effect, progesterone may also affect excitatory mechanisms. In studies performed by Smith et 
al. (1987) it was shown that after systemic or topical application of the steroid in Purkinje 
cells from cat, both progesterone and several metabolites decreased glutamate responsiveness. 
Progesterone therapy has been beneficial in the treatment of catamenial epilepsy (Mattson et 
al., 1984; Herzog 1995, 1999 a, b).
4.5.3 Androgens
The effect of androgens on seizure susceptibility is more complex. Whilst testosterone lowers 
the seizure threshold, increases PTZ seizures, and enhances the development of amygdala-
kindled seizures (Edwards et al., 1999; Reddy, 2004a), androgens also show an anticonvulsant 
effect, probably mediated by their interactions with the GABAA receptor (Frye and Reed,
1998; Reddy 2004b).
4.6 MEDICATION AND GENDER-SPECIFIC ISSUES
4.6.1 Enzyme-inducing drugs
Phenobarbital (PB), PHT, and CBZ are all inducers of hepatic microsomal enzymes, and thus 
accelerate the metabolism of other drugs, and also the breakdown and production of SHBG. 
This increases SHBG, and reduces free, circulating androgens and oestrogens, resulting in a
decreased level of biologically active sex hormones (Macphee et al.,1988; Isojärvi et al.,
1988, 1990a, b, 1991; Rättyä et al., 2001; Murialdo et al., 1994, 1998). In a randomized study 
by Mattson et al. (1985), impotence and decreased libido was reported in 16 % of epilepsy 
patients starting monotherapy with PB, 12 % after starting PHT, and 13 % after starting CBZ. 
Elevated oestradiol has also been found in men with epilepsy taking PHT (Isojärvi et al., 
1990a; Herzog, 1991; Murialdo et al., 1994). Associations between high oestradiol levels and
sexual dysfunction have been found in some men (Herzog, 1991). CBZ has not been found to 
elevate serum total testosterone or oestradiol, but an increase in SHBG decreases the level of 
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free androgens (FAI = free androgen index) (Mcphee et al., 1988; Isojärvi et al., 1988, 1990a,
1991, 1995a, b; Isojärvi, 1990b; Rättyä et al., 2001). In some men, sexual dysfunction arises
after long-term CBZ treatment. In women taking CBZ, a similar pattern occurs as in men,
with a progressive increase in SHBG. This results in a decreased amount of bioactive 
oestradiol, which can be associated with menstrual disturbances after long-term treatment. 
Low serum dehydroepiandrosteronsulphate (DHAES) has also been reported in men and 
women taking PHT and CBZ (Macphee et al., 1988; Isojärvi, 1990b; Levesque et al., 1986). 
DHAES is a weak androgen, secreted from the adrenal cortex, and the clinical implication of
low DHAES is unknown. 
Both CBZ and PHT have been associated with changes in semen quality (Chen et al., 1992),
and two relatively recent studies have shown that CBZ is associated with reduced sperm 
motility and increased frequency of morphologically abnormal sperm (Røste et al., 2003;
Isojärvi et al., 2004). 
Despite these findings there is no obvious significant reduction in fertility in patients using 
enzyme-inducing AEDS (EIAEDs) (Artama et al., 2006).
4.6.2 Valproate
Although VPA was introduced in the early 1960s, the first systematic report on VPA 
suggesting reproductive endocrine disturbances was not published until 1993 (Isojärvi et al.,
1993). Since then numerous studies have been published, showing a high incidence of 
menstrual disturbances, linked to obesity, hyperandrogenism, and PCO (Isojärvi et al., 2001,
2005; Murialdo et al., 1998; Vainionpää et al., 1999; Morrell et al., 2003; Luef et al., 2002). 
Development of PCO seems to be especially common when VPA is started before 20 years of 
age  (Isojärvi et al., 1993; Vainionpää et al., 1999), but also occurs when VPA treatment is 
started later in life. It has been suggested that this reproductive disorder could be secondary to 
obesity, but PCO also occur in lean women (Isojärvi et al., 1996, 2001). In obese women,
hyperinsulinemia and low insulin growth factor binding protein1 (IGFBP-1) have been found. 
Insulin and insulin growth factor 1 (IGF-1) are well recognised as stimulants of ovarian 
androgen synthesis (Giudice, 1992; Conover et al., 1992). Testosterone levels are elevated in 
both lean and obese women using VPA (Isojärvi et al., 1996, 2001), but insulin and IGFBP-1
are only elevated in obese women. The endocrine effects caused by VPA are at least partially
reversible (Isojärvi et al., 1998). In the 1990s, the endocrine side-effects of VPA were heavily 
debated, especially the issue of VPA’s association with PCOS (Genton et al., 2001; Isojärvi et 
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al., 2001; Bauer et al., 2000). As VPA is not associated with elevated LH levels (Isojärvi et 
al., 1993, 2001; Murialdo et al., 1998; Rättyä et al., 2001), it is unlikely that it stimulates
ovarian androgen synthesis via LH secretion. The endocrine effect of VPA occurs in the 
ovary, where it acts as an enzyme inhibitor, inhibiting the conversion of testosterone to 
oestradiol (Peruccae et al., 1984), and this hypothesis is supported by results from various 
animal studies (Gregoraszczuk et al., 2000; Taubøll et al., 2002, 2003; Røste et al., 2002).
High levels of testosterone in the ovary will arrest follicular maturation and promote the 
development of PCO (Hsueh et al., 1984). Persons using VPA for reasons other than epilepsy 
also have more menstrual disturbances and PCO than controls (O’Donovan et al., 2002). In 
total, these data suggest that the epilepsy per se, is unlikely to be the reason for the endocrine 
changes seen in women taking VPA.
In men, VPA reduces serum levels of gonadotropins and androstenedione (Rättyaä et al., 
2001; Isojärvi et al., 2004). Cases of infertility have been noted in males using VPA. VPA has 
been shown to affect sperm motility and is associated with an increase in frequency of 
morphologically abnormal sperms (Isojärvi et al., 2004; Røste et al., 2003).
4.6.3 Lamotrigine
Studies of lamotrigine (LTG) in both animals and humans (men and women) have not 
detected any endocrine side-effects (Herzog et al., 2004; Isojärvi et al., 1998; Biton et al.,
2001; Røste et al., 2001). LTG is therefore generally regarded as safe with respect to 
endocrine side-effects. However, LTG has recently been found to interact with oestrogens,
such that LTG concentrations are reduced when oestrogens levels are high, due to use of birth 
control pills (Reimers et al., 2005; Christensen et al., 2007).
4.6.4 Levetiracetam
Levetiracetam (LEV) is a relatively new, broad-spectrum AED with positive reports 
regarding both effects and side-effects (Ben-Menachem, 2003). Recent studies have shown a 
promising effect of LEV on generalized epilepsies like tonic–clonic, absence, and myoclonic 
epilepsy, for which VPA has previously often been the drug of choice (Krauss et al., 2003; Di 
Bonaventura et al., 2005; Labate et al., 2006). Safety data indicate that LEV is well tolerated 
by the majority of patients, and endocrine side-effects have not been reported in humans to 
date (Ben-Menachem, 2003; Harden, 2001; Briggs and French, 2004). However, a recent 
study, utilizing ovarian follicular cells from prepubertal pigs, demonstrated that LEV affects 
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basal steroid hormone secretion (Taubøll et al., 2006) indicating an effect of the drug on 
steroidogenesis. LEV does not seem to act by any of the main mechanisms currently accepted 
for AED anti-seizure action (GABAergic facilitation, inhibition of Na+ channels, or 
modulation of low-voltage activated Ca2+ current) (Lynch et al., 2004). LEV binds to a 
synaptic vesicle protein, SV2A (Lynch et al., 2004), which is widely distributed in most 
endocrine tissue (Buckley and Kelly, 1985; Portela-Gomez et al., 2000; Bajjalieh et al., 1994),
including male gonads (Bajjalieh, personal communication). Specific information regarding
the ovary is currently unavailable. However, these data suggest a possible means by which
LEV may influence endocrine function.
5. AIMS OF THESIS
1) To investigate whether menstrual disturbances are more frequent among women with 
epilepsy than in the general population.
2) To investigate whether menstrual disturbances in women with epilepsy are associated with
epilepsy type, seizure severity, type of AED used, and use of mono- or polytherapy. 
3) To investigate whether epilepsy affects age of menarche, and whether the natural endocrine 
changes during puberty can result in debut of epilepsy.
4) To use a female animal model to investigate the occurrence of endocrine side-effects 
associated with use of the new drug LEV.
5) To use a human study to investigate whether the results of the animal study (pt. 4) are of 
clinical relevance.
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6. SUMMARY OF PAPERS
6.1 PAPER 1
The aim of this study was to examine the frequency of menstrual disturbances in a large 
population of epilepsy patients, which had not been specifically selected. Most previous
investigations of menstrual disturbances in epilepsy patients have been small and based on a
limited patient group, often focussing upon poorly functioning patients from tertiary care 
centres.
A retrospective questionnaire of a cohort of female outpatients, aged between 18 and 45
years, was conducted. In order to optimise controls, regarding age and lifestyle, each patient 
chose a close female friend who agreed to serve as a control. 
Completed questionnaires were received from 265 patients and 142 controls. Menstrual 
disturbances were more frequent in patients with epilepsy (48.0 %) than in controls (30.7 %)
(P = 0.004). Menstrual disturbances were more frequent in patients on polytherapy than on 
monotherapy (P = 0.049), and more frequent in patients with high seizure frequency (> 5
seizures/year) than in patients with a lower seizure frequency or free of seizures (P = 0.006). 
The frequency of menstrual disturbances was higher in patients using VPA than CBZ
monotherapy (P = 0.045).
The investigation confirmed that women with epilepsy have an increased frequency of 
menstrual disturbances compared with women without epilepsy. In women with high seizure 
frequency and/or using polytherapy, the frequencies of menstrual disturbances are increased
yet further. The highest frequency of menstrual disturbances occurred in women using the 
AED, VPA.
6.2 PAPER 2
In this study we wanted to investigate the relationship between debut of epilepsy and 
age of menarche in a large population of female epilepsy patients. We were interested in 
discovering whether sexual maturation in puberty could induce the debut of seizures, as has 
been previously indicated in some studies. We also wanted to explore the possibilty that 
epileptic activity could induce alterations in pubertal endocrine maturation and thereby age of 
menarche. 
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A retrospective, questionnaire of a cohort of 265 female outpatients from three 
Norwegian hospitals, and 142 controls, aged between 18 and 45 years, was conducted. 
Parameters regarding epilepsy and reproductive health issues were registered. Perimenarche 
was defined as the periods 2 years before and 2 years after the year of menarche. 
We found a significantly higher frequency of patients with epilepsy debut between 10 
and 18 years compared with a younger age-group (0 - 9 years; p < 0.01). However, there was 
no significant difference in occurrence of epilepsy debut in the perimenarche period compared 
with the 5 year periods before and after perimenarche, and no significant difference in 
epilepsy debut in the year of menarche compared with the 5 years before and after menarche.
Age at menarche did not differ significantly in those with epilepsy debut before menarche 
from those with debut after menarche. Epilepsy type (idiopathic generalized or partial) did not 
influence the age of menarche. 
This study did not confirm former observations of clustering of epilepsy debut at 
menarche nor in the perimenarche period, or alterations in age of menarche in girls with 
epilepsy. However, onset of epilepsy was more frequent in the adolescent age group than in 
childhood.
6.3 PAPER 3
The aim of this study was to investigate possible effects of LEV on endocrine function 
and ovarian morphology in non-epileptic rats. LEV is one of the newer AEDs and endocrine 
side-effects have not previously been reported in humans. However, a study on ovarian 
follicular cells from prepubertal pigs showed that LEV affected basal steroid hormone 
secretion.
Thirty female Wistar rats were fed per-orally with either 50 mg/kg LEV (n = 15) or 150
mg/kg LEV (n = 15) twice daily for 90 - 95 days. Twenty rats received a control solution. 
There was a significant, dose-dependent increase in mean ovarian weight after LEV 
treatment. Mean numbers of ovarian follicular cysts were unchanged, but there were 
significantly more corpora lutea and secondary follicles in the treated animals. Serum 
testosterone was significantly increased in treated animals (0.50 nmol/l versus 0.16 nmol/l in 
controls, p < 0.05), while oestradiol was reduced (67.4 compared with 257.5 pmol/l in 
controls, p < 0.05). The low-dose group had significantly higher serum progesterone 
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concentrations than the control group (56.8 nmol/l versus 34.7 nmol/l, respectively, p < 0.05). 
FSH was lower in the treated animals (3.3 ng/ml versus 5.5 ng/ml, p < 0.05) while LH was 
unaffected.
Our findings indicate a possible effect of LEV on the hypothalamic-pituitary-gonadal 
(HPG) axis and ovarian morphology in non-epileptic rats. These effects have not previously 
been described for other AEDs.
6.4 PAPER 4
The aim of this study was to investigate whether men and women with epilepsy and 
treated with LEV exhibited differences in serum hormones, compared with epilepsy patients 
using CBZ or LTG in monotherapy for epilepsy, and compared with healthy controls. Sexual 
function was also assessed and compared.
A total of 306 subjects, aged between 18 and 45 years, participated in the study. The 
epilepsy patients had been using LEV (30 men, 26 women), LTG (37 men, 40 women), or 
CBZ (63 men, 30 women) monotherapy for at least 6 months. 36 men and 44 women served 
as healthy controls. Blood samples for hormone analyses were collected, and questionnaires
completed for asessing sexual function (ASEX) and other health-related factors.
No endocrine changes were found in women using LEV, but SHBG was higher and 
progesterone lower in women using CBZ. In women using LTG, concentrations of DHEAS 
were higher and androstenedione lower. ASEX scores were significantly lower in female 
patients using LTG or LEV than in patients using CBZ and than in control subjects, indicating 
that LTG and LEV use were associated with improved sexual function in women.
No specific hormonal patterns were identified in the men treated with LEV. Male 
patients in all treatment groups had lower androstenedione and free testosterone
concentrations than control subjects. Men using CBZ had a lower FAI and DHEAS
concentration, and higher SHBG, FSH, and LH concentrations. ASEX scores for men were 
similar in all groups.
We found no drug specific hormonal effect of LEV in either men or women. Women 
treated with LTG or LEV were more satisfied with their sexual function than patients treated 
with CBZ and than healthy controls, while sexual function in males appeared to be unaffected 
by treatment. The results of this study did not confirm our results from the animal study
regarding LEV.
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7. DISCUSSION
In paper 1 we focus on menstrual disturbances in women with epilepsy. Several 
previous studies have shown an increased frequency of menstrual disturbances in women with 
epilepsy (Bilo et al., 1988; Herzog et al., 2003a; Morrell et al., 2002), but one problem with 
some of these studies is that the controls are poorly matched to the patient group. The optimal 
situation is that the control group consists of persons that differ only from the patient group 
with respect to the diagnosis and its treatment. Socioeconomic environment and health status
(regarding non-epilepsy diseases) in the two groups should be as similar as possible. In order 
to optimise the control group in our study, the epilepsy patients were asked to choose one 
close friend for the control group questionnaire. We believe that this matching procedure for 
choice of control group was good, because the friends chosen were usually about the same age 
and weight as the patients and probably from the same social environment. The intention was 
to analyse patients and controls as individual pairs, but as we received completed 
questionnaires from 265 patients but only 142 controls this approach was not possible. 
Nevertheless there were sufficient controls for statistical comparison between groups.
Another problem with former studies has been that the participating epilepsy patients 
often have a severe epilepsy burden (many seizures, polytherapy etc.), and are therefore 
probably not a good representation of women with epilepsy in the general population. The 
aim of our investigation was to study an unselected group of patients, representative of the 
whole epilepsy group, except for those with major mental deficits. We also wanted to focus 
upon a relatively healthy group of epilepsy patients in order to minimize ambient factors
which may have impacted on the results. By examination of patient registries at the 
participating hospitals, we were able to include all women in the right age group (between 18
and 45 years), excluding those with major intellectual deficits who would not be capable of
answering the questionnaires. 
The response rate achieved in this study was 53 % (265/500). In order to determine whether
the non-responders differed from the responders, we examined medical records from 45 of the 
non-responders. Analysis of age, epilepsy debut age, seizure type, and medication 
demonstrated that the only parameter that differed between the responder and non-responder 
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groups was age of epilepsy debut, which was about three years lower in the non-responder 
group.
In this large study of 265 epilepsy patients we found a clear elevation in 
menstrual disturbances among epilepsy patients (48 %), compared with women without 
epilepsy (30.7 %) (p = 0.004), although menstrual disturbances were common in both groups. 
However, as the exact value within each group is dependent on the definition of a menstrual 
disturbance, and this definition often varies between different studies, it is the difference 
between the groups that is of greatest interest, rather than the exact percentages. In this study a
menstrual disturbance was defined by the examiner (according to Polsen et al., 1988), rather 
than by the patient, on the basis of answers provided to ten questions about the regularity and 
duration of menstrual periods. This is probably a relatively sensitive method for detection of 
menstrual disturbances, and obviously both patients and the controls answer exactly the same 
questions. One problem could have been the retrospective design of the study, which can 
always be influenced by recall-bias, but this problem would have affected both groups 
equally.
Following the detection of an increased frequency of menstrual disturbances in women 
with epilepsy, the next step was to explore the aetiology of the menstrual disturbances. Which 
factors were likely to be of importance: the drug treatment? the location of epileptic focus? 
the EEG pathology? the psychosocial burden of having a chronic disease? In this study we 
were able to address some these questions. We found more menstrual disturbances among 
women using VPA monotherapy than CBZ monotherapy. This result can probably only be 
explained by the use of the different AEDs. The blinded design of this study made a sub-
classification of seizures due to localisation impossible, but primary generalized seizures 
could be separated from partial seizures and we were unable to detect any difference in 
frequency of menstrual disturbances between these two groups. Only the CBZ and VPA
monotherapy groups were large enough for meaningful comparisons between epilepsy types.
We did not find significantly more menstrual disturbances in the group of patients using CBZ 
monotherapy for generalized seizures (45.5 %, n = 22) than in the group using CBZ for partial 
seizures (36.4 %, n = 33) (p = 0.22). In patients using VPA in monotherapy for generalized 
seizures the number of menstrual disturbances was not significantly higher than in the group 
using VPA for partial seizures (63.6 % and 55.5 %, respectively). However, there was a
higher percentage of menstrual disturbances in women with generalized seizures, in both the 
CBZ group and the VPA group, but the differences were not significant. These results
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demonstrate that menstrual disturbances in the study were independent of seizure type 
(primary generalized vs. partial onset), but the possible endocrine effects of the epileptic focus 
occurring in specific areas of the brain were not explored.
The occurrence of more than five seizures during the previous 12 months was associated 
with more menstrual disturbances. Patients with more seizures may have more epileptic 
activity in their EEG, so it is possible that the epileptic activity contributes to the menstrual 
disturbances. However, exploration of this hypothesis is complicated by the fact that patients 
in this group use more AEDs than patients with fewer seizures, and it is very difficult to 
investigate these two factors separately in human clinical studies.
Although experiencing irregular menses is not necessarily a problem per se, it can be an 
indicator of hormonal irregularities that can cause alterations in fertility and sexual life, as
well as impacting upon more cosmetic alterations in fat distribution and body-hair pattern. 
Infertility is the most serious problem caused by hormonal changes. Although this study 
was not intended or designed to investigate infertility induced by epilepsy or its treatment, we 
nevertheless noted that the women in the control group had more children per women (1.1
children per woman) than the patients (0.8 children per woman). The reason for this small 
difference can be multifactorial and is not necessarily caused by infertility. Infertility caused 
by epilepsy or AEDs in a subset of patients could be more usefully investigated in a 
prospective study. 
We wanted to use this large population of 265 epilepsy patient and 142 controls to study 
other relevant endocrine issues. Several human and animal studies have demonstrated that 
oestrogens facilitate seizures by lowering the seizure threshold. In the period of 2 to 4 years 
before menarche, oestrogen production in girls starts to increase. Secretion of progesterone, 
which has the opposite effect on seizure threshold, starts after the first menstruation. As some 
studies have shown clustering of epilepsy debuts in the years around menarche (Klein et al.,
2003; Morrell et al., 1998) we were interested in exploring this possibility in our study 
population. Thirty patients were excluded from this arm of the study because their epilepsy 
was secondary to neurodegenerative disorders, vascular diseases, multiple scleroses etc., and 
therefore probably less likely to be influenced by hormones, and we included only those
patients with epilepsy debut between the ages of 0 and 18 years old. This enabled us to 
exclude those individuals for whom other causes of epilepsy were more likely.  Although we
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found a higher number of patients with debut of epilepsy in the age group between 10 and 18
years than in the age range between 0 and 9 years, we did not reproduce the findings of Klein
et al. (2003) which showed a clustering of epilepsy debut in the 2 years before and after the 
year of menarche. As oestrogen increase can start more than 4 years before menarche, it is 
possible that only investigating two years before menarche was too short a period to 
demonstrate a clustering effect in our patient group. Other possible explanations for the 
increase in epilepsy debut between the ages 10 and 18 years can be multifactorial; important 
lifestyle changes often occur during adolescence including decreased sleep, introduction of 
alcohol, and disruption of routines. These factors are all known to provoke seizures. Some 
common epilepsy syndromes, such as juvenile myoclonic epilepsy, also tend to start between 
10 and 18 years of age. One weakness in our study is that we did not follow the entire female 
population. The participants were between 18 and 45 years, and therefore individuals who 
developed epilepsy in childhood, but recovered before the age of 18, were not included. This 
exclusion might have affected our results.
The final issue we wanted to investigate in this population was whether epilepsy was 
associated with delaying or hastening menarche. We compared menarche age in patients with
debut of epilepsy prior to menarche with those whose epilepsy debut had occurred after 
menarche. Mean ages of menarche for each group were 13.2 and 12.7 years, respectively,
which is not significantly different (p = 0.071). Additionally, no difference in menarche age 
could be detected between those suffering from partial or generalized epilepsy, indicating that 
for large groups of women with epilepsy, their epileptic discharges probably do not affect
important hormonal systems like puberty and menarche. It would have been interesting to 
explore whether having many seizures and much epileptic activity in EEG was associated 
with timing of menarche, but detailed EEG information on the patients was unavailable.
One reason why assocations between menarche/puberty and epilepsy debut/exacerbation 
of seizures are interesting, is because they provide an indication of the extent to which 
hormones influences epileptic seizures in humans. The influences of oestrogens and 
progesterone on seizures have been studied closely in in vitro and animal models, but 
although several studies have investigated menstrual cycle related seizures (catamenial) and 
some have explored associations between menopause and seizures, in this phase the results 
are more complex and difficult to interpret. Knowledge on this subject is likely to be 
important for optimising treatment of epilepsy during different life stages and might also give 
further insights regarding the normal fluctuation of the disease. 
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In paper 1, we found that menstrual disturbances were more frequent in women using 
VPA and polytherapy than in other women with epilepsy, supporting the need to improve our
knowledge regarding the endocrine potential of different AEDs.  Many patients start using 
AEDs as children and continue to use them for several years, often throughout life. LEV is a 
relatively new drug, with a mode of action which differs from that of all well-known and 
established AEDs. Our knowledge about binding to a synaptic vesicle receptor, SV2A, is
relatively recent, but it is thought that the effect of LEV is mediated through this binding. The 
SV2A receptor occurs in several places in the central nervous system and in almost all 
endocrine tissue, and therefore having a complete understanding of LEV’s effect on the 
endocrine system is especially interesting. The field of indications for use of LEV is 
continuously increasing, and therefore more and more patients are using this AED. Thus, we
were particulary interested in exploring the possibility of endocrine side-effects associated 
with use of LEV.
Our initial studies were based on a rat model previously used to study endocrine side-
effects of VPA. In order to mimic long-term treatment in humans, the rats received LEV 
treatment for between 90 and 95 days. During this period the rats would have experienced 
approximately 20 menstrual cycles, the equivalent of which would normally take about 1.5 - 2
years in women. 
Choice of drug dose in such studies can be difficult, because rats and humans do not 
necessarily metabolize drugs by the same pathways. The recommended serum concentration 
for LEV is broad and has altered over time as more experience of the drug has been acquired.
A publication from 2008 (Patsalos et al., 2008) recommends a reference range from 70.5 - 270
µmol/l, but when our studies were planned the recommended range was 40 - 130 µmol/l. In 
order to find the most suitable dose for our study, three different doses (50 mg/kg, 100 mg/kg 
and 150 mg/kg) were tried initially; after monitoring serum concentrations, we decided to 
continue with the highest and lowest of these doses. The serum concentrations of LEV 
fluctuated over the course of the day, being high during the first few hours after feeding and 
then gradually declining. In humans, serum concentrations are usually measured as fasting 
values, about 12 hours after the last dose. The serum concentrations that are reported in our
paper (high dose animals, 277 µmol/l; low dose animals, 122 µmol/l) are those measured at 
euthanasia, about 4 hours after the last dose of LEV.
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Several differences between the treatment groups were found, regarding both ovary 
morphology and serum hormones. Ovary weight was higher in the treated rats, and the weight 
increase was dose dependent. More secondary cysts and corpora lutea were found in the 
treated animals. Although few cysts were found in any of the animals, regardless of treatment, 
the low dose treated animals had the least. As an isolated finding, these findings could 
indicate a drug-induced effect, resulting in bigger and heavier ovaries due to higher ovarian 
activity with production of more ova (and therefore more follicles and corpora lutea). This 
could, per se, be considered a positive effect, resulting in increased fertility. These 
morphological findings differ from those found in rats treated with VPA (Røste et al, 2002),
in which VPA treated rats had more ovarian cysts, fewer corpora lutea, and reduced ovary 
weight compared with controls. Thus the effects found with LEV appear to be drug-specific, 
rather than nonspecific AED-treatment effects.
The hormone measurements showed higher testosterone and lower oestradiol in the 
treated animals, whilst FSH was lower. The reason for these findings is not obvious and 
several possible explanations are discussed in the paper. A suppression of FSH could affect 
both follicular development and disturb ovarian steroid secretion. Testosterone is the principal 
ovarian secretory product in follicles deprived of FSH, but this does not explain the high 
number of corpora lutea nor the elevated progesterone concentrations. Induction of a pseudo-
pregancy-like state, in which corpora lutea are activated and secrete prolactin and persist for 
much longer than normal, can also induce follicle growth and reduce oestradiol levels, and 
such a scenario is a plausible alternative explanation. Pseudo-pregnancy is readily induced in 
rats by taking vaginal smears (Smith et al., 1975). Nevertheless we consider our method 
useful; all animals were handled identically, regardless of treatment group, and were selected 
randomly with respect to time of vaginal smear and also euthanasia. Thus the handling 
procedures would affect the animals in all groups equally. The same method was used in a
previous experiment on VPA and hormonal side-effects (Røste et al., 2001), and the findings 
from that study were comparable with results for other research, and also transferable to 
humans. Therefore we believe that our results are of importance and worthy of follow-up in 
human clinical studies.
A study on ovary cells in prepubertal pigs (Taubøll et al 2006) concluded that LEV
affected the conversion of testosterone to oestradiol after FSH stimulation of the ovary cells, 
but only at high drug levels. In basal conditions (without gonadotropins present) testosterone 
was increased and oestrogen reduced (only at high LEV concentrations). This study supported
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some of the results from our study, and thus increased our interest in proceeding further to 
human, clinical studies on LEV.
Our animal model study was one of the first to explore possible endocrine side-effects 
from LEV, and as pronounced effects were identified, which differed from those found with 
other AEDs, we considered it essential to continue our investigations and discover whether 
these animal model results were transferable to humans.  
In paper 4 we investigated possible endocrine side-effects of LEV in human subjects. We 
wanted to perform a cross-sectional study in order to maximise patient numbers. We also 
wanted to include only persons on LEV monotherapy in order to reduce the effects of 
concomitant factors on our results. However, at the time of the study LEV was quite new in 
Norway and only supplied as an add-on to other drugs. Therefore, as insufficient patients were 
available in Norway for this study design, we chose to cooperate with a centre in Innsbruck, 
Austria. Cross-border cooperation provides new challenges and it is important to ensure that 
the same inclusion and exclusion criteria are followed. In order to address some potential
problems, all the blood samples were frozen and all the hormone analyses were conducted in 
the same laboratory in as few batches as possible. As cultural differences may also exert an 
effect e.g. regarding answers to the sexual-function questionnaire, despite both Norway and 
Austria being highly-developed European countries, we included a further 30 control subjects 
from Austria (15 male and 15 female) in the questionnaire section of the study.
In order to find specific gender-related effects, we wanted to include both male and female 
participants in this study and we also wanted to compare the effects of LEV on particular 
parameters, not only with those in healthy controls, but also in epilepsy patients of the same 
age groups but using older drugs with well known endocrine potentials. Thus, epilepsy 
patients using CBZ or LTG were also included in the study.
Endocrine changes were not detected in either men or women using LEV. Hormone 
levels were not statistically different from those in controls, and the women using LEV did 
not report more menstrual disturbances. Whilst these results are clearly encouraging for the 
patients and their doctors, the discrepancies in results from the human and animal studies need 
to be considered.
One reason for the discrepancy could be that animals and humans react differently to
LEV exposure. We consider this to be rather unlikely because when the same model was used
for investigating VPA treatment, studies from rats and humans provided similar results.
However, LEV is a different drug from VPA with a different mode of action, and therefore 
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there may be differences in effects between species. If this is not the explanation, we must 
explore whether the dissimilar results might be explained by other factors, such as exposure 
time to the drug, age of participants etc. In the rat study, the exposure period was 90 days or 
approximately 20 cycles, which is longer than in the human study, in which the shortest 
exposure time was 6 months (although most patients had been using the drug for a longer 
period). In the human study, the age of the participants was between 18 and 45 years, whilst in
the animal model the rats were 120 days old when they started LEV treatment. Compared 
with humans, this resembles a young population of fertile females. In the study of Taubøll et 
al. (2006) which investigated the effect of LEV on ovarian cells, the cells were taken from 
prepubertal rats.  Therefore, an effect of LEV on younger females than those included in 
paper 4, where the mean age was 29.2 years (males: 30.2 years), cannot be excluded.
It is also important to remember that the study in paper 4 was cross-sectional and 
therefore effects in a subgroup of patients could have been masked due to the study design. In 
a prospective study, all the participants could have been followed regularly, and an effect in 
individual patients would have been readily observed. In a recent abstract (Harden et al.,
2008) eleven male patients were followed for four weeks after commencing LEV treatment 
and total testosterone and free testosterone concentrations were found to increase in seven and 
eight patients, respectively. Our study cannot rule out an effect in sub-groups of individual 
patients.
As a further measure of endocrine function, a questionnaire on sexual function was 
included in our study. Female epilepsy patients on LEV and LTG reported better sexual 
functions than both the controls and the patients being treated with CBZ. Men in all groups 
reported a high degree of sexual contentment and there were no differences in sexual function 
between groups. The difference between female controls and patients treated with LEV and 
LTG was surprising and interesting. One possible explanation could be the psychotropic 
effects of the drugs; LTG has been used for treatment of depression and bipolar disorders for 
years, and has beneficial effects on quality of life (Zarzar et al., 2007) and mood stabilisation 
(Miller et al., 2008). LEV is not approved for use in psychiatric conditions, but some studies 
have indicated that it may have a beneficial effect on mood disorders (Ciesielski et al., 2006; 
Muralidharan and Bhagwagar, 2006; Mazza et al., 2008). Another explanation could be that 
our control group had higher scores than expected in the population. One of the study 
exclusion criteria was use of hormonal contraception, and thus it is temping to speculate that 
perhaps the most sexually active women were excluded from the study due to their more 
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frequent use of contraceptive pills, hormonal IUD etc. It should be noted that women with 
epilepsy are often advised against the use of hormonal contraception because of the potential 
for interactions with AEDs. 
The intention in our study was to have an unselected out-patient group, from secondary 
care hospitals, as the study subjects. Many studies in which a marked sexual dysfunction has 
been reported have recruited their study patients from tertiary care centres. Such patients often 
have more seizures, greater comorbidity, and use more AEDs. Studies with patients similar to 
those in our study have provided results which support those that we found (Jensen et al., 
1990; Gil Nagel et al., 1990). A relatively new study on adolescents (deVincentiis et al., 2008) 
concluded that adolecents with epilepsy usually have normal sexual functions. Thus, we can 
conclude that in this patient group the risk of sexual life being severely affected by epilepsy 
and medication with LEV, LTG, or CBZ in monotherapy, is low.
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8. CONCLUSIONS
1. Women with epilepsy have an increased frequency of menstrual disturbances.
2. Menstrual disturbances are more frequent in women with high seizure frequency, 
using VPA, and using polytherapy.
3. Debut of epilepsy seems to be more frequent in the adolescent age group (between 10
and 18 years), than in childhood (between 0 and 9 years), without a clustering in the 
perimenarche; epilepsy does not influence the time of menarche. 
4. Long-term treatment with LEV in female rats changes ovarian morphology, resulting 
in more secondary follicles and corpora lutea, and increased serum testosterone and 
reduced oestradiol.
5. In men and women aged between 18 and 45 years, treatment with LEV does not alter 
sex hormones or sexual function.
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9. FUTURE CHALLENGES
As this research has emphasised, there are several close associations between epilepsy, 
hormones, and AEDs. Epilepsy is common in childhood and in the fertile years, and therefore 
it is very important that our knowledge on the endocrine potential of all AEDs is as broad and 
as detailed as possible.
Our human clinical study provided promising results regarding the use of LEV, but 
further endocrinological questions remain to be answered. Studies of porcine cell cultures 
(Taubøll et al., 2006) indicated that LEV may have effects on ovary cells deprived of
gonadotropins, as is the situation in pre-pubertal children. Endocrine studies should therefore 
be conducted in children and teenagers. Additionally, our lack of data on the possibility of
endocrine effects developing after many years of LEV treatment indicates that prospective, 
long-term studies in adults should also be performed.
All new AEDs should be investigated for possible endocrine effects before they are
approved for common use. We recommend that a useful approach would be to use a battery of 
experiments, starting with experimental endocrine cell models (ovary and testes cells), and
followed by studies in whole animals, of both sexes and at different ages. As drugs can have 
gender-specific effects and the effects can vary between different developmental ages, it is 
important that these aspects are not neglected. Finally, tests for hormonal side-effects should 
be a mandatory part of the human testing programme prior to approval.
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